Mayo Clinic Laboratory and pathology research roundup: June 6
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Utilizing mass spectrometry to detect and isotype monoclonal proteins in urine: Comparison to electrophoretic methods.
Matrix assisted laser desorption ionization time of flight mass spectrometry coupled to immune enrichment (MASSFIX) as an alternative to serum immunofixation electrophoresis has demonstrated increased sensitivity in monoclonal protein (MP) detection with improved laboratory workflow. This study explored similar replacement of urine immunofixation electrophoresis (u-IFE) with urine MASSFIX (u-MASSFIX) by method comparison.
Published to PubMed This Week
- Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome.
Rheumatology - Renal involvement in systemic sclerosis.
Autoimmune reviews - Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience.
Human Pathology - Evidence for angiotensin II as a naturally existing suppressor for the guanylyl cyclase a receptor and cyclic GMP generation.
International Journal of Molecular Science - MICon - A contamination detection workflow for NGS laboratories using microhaplotype locus and supervised learning.
Journal of Molecular Diaganotics - Use of the HEAR score for 30-day risk-stratification in emergency department patients.
American Journal of Medicine - Using AI to detect pain through facial expressions: A review.
Bioengineering (Basel) - Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance.
Journal of Applied Laboratory Medicine - Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C.
Cancer research
